COVID-19 Clinical Features and Outcomes in Elderly Patients during Six Pandemic Waves

Roxana Manuela Fericean, Ovidiu Rosca, Cosmin Citu, Diana Manolescu, Vlad Bloanca, Ana-Olivia Toma, Estera Boeriu, Catalin Dumitru, Madhavi Ravulapalli, Vlad Barbos, and Cristian Oancea

Abstract: Many elderly patients with severe SARS-CoV-2 infections and COVID-19 infections are admitted to intensive care units. Age was previously identified as an independent risk factor for death and contributed to the greater severity of COVID-19. The elderly may have diminished lung functions, poor reactions to artificial ventilation, and compromised immune systems. However, it is yet uncertain how each pandemic wave and the predominant SARS-CoV-2 strains contribute to varying results and how patient groups such as the elderly are impacted. Comparing six COVID-19 pandemic waves, the objective of this study was to examine the variation in case severity, symptomatology, ICU hospitalizations, and mortality among SARS-CoV-2-infected elderly individuals. The study followed a retrospective design, including 60 eligible patients older than 70 years in each of the six pandemic wave groups, after matching them by the number of comorbidities and gender. SARS-CoV-2 infection during the first, third, and fourth pandemic waves had a significantly higher risk of mortality for hospitalized patients. Confusion and dyspnea at admission were significant risk factors for ICU admission in elderly patients. The laboratory parameters identified decreased lymphocytes (β = 1.92, respectively), elevated IL-6 (β = 1.96), and procalcitonin (β = 2.46) as the most significant risk factors. The third and fourth COVID-19 waves had considerably more severe infections (31.7% and 26.7%) than the sixth wave (13.3%). Median ICU stay and β-risk factors for ICU admission in elderly patients.
in an increase in infections and a strain on healthcare systems, which might explain the variations found in our research.

**Keywords:** COVID-19; SARS-CoV-2 infection; elderly patients; viral epidemiology; infectious diseases

---

**1. Introduction**

In most individuals, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces no symptoms or moderate symptoms; it is less lethal than other viral infections, even though 20% of cases, such as those involving elderly persons and those with numerous comorbidities, may develop severe forms and immune system overactivation [1–3]. The symptoms of coronavirus disease 2019 (COVID-19) include fever, fatigue, and a dry cough. Interstitial pneumonia, thrombo-embolic events, and acute respiratory distress syndrome (ARDS) are all potential severe symptoms of SARS-CoV-2 infection in at-risk groups such as the elderly [4–7]. Overactivation of the immune system, triggering a cytokine storm, may produce these effects, although a wide variability of clinical outcomes was hypothesized to exist between circulating SARS-CoV-2 variants [8,9].

All age groups are vulnerable to SARS-CoV-2 infection, and the median hospitalized cohort age is 50–60, with a higher rate of intensive care unit (ICU) admissions and mortality after the age of 65 [10–12]. Men are more likely to have SARS-CoV-2 than women of comparable age, and they have a higher prevalence among hospitalized patients needing critical care, which may indicate a difference in severity; although, recent investigations had divergent outcomes [13–15]. These symptoms and manifestations have remained all throughout the COVID-19 pandemic development, with almost three years since its onset. However, several investigations show that different SARS-CoV-2 genotypes display different symptomatology and infection severity [16,17].

Many elderly COVID-19 patients with severe infections are admitted to critical care units with elevated inflammatory markers and D-dimer concentrations. The inflammatory cell infiltration in the lungs triggers the cytokine storm syndrome in COVID-19 patients [18–20]. Some experts feel that rapid treatment of this cytokine storm in its early stage with immunomodulators, corticosteroids, and cytokine antagonists is an essential component in decreasing mortality rates and reducing ICU hospitalizations [21–23]. Aging contributes to the increased severity of COVID-19, and it was previously observed as an independent risk factor for mortality. Elderly individuals may have reduced lung function and a poor response to mechanical ventilation, as well as a weakened immune system [24–26].

Although the COVID-19 vaccination campaign was spread worldwide by early 2021, reaching an impressive number of vaccinated patients until 2022, the efficacy of two or even three doses started to become lower as time passed, and the SARS-CoV-2 virus continued suffering different mutations [27–31]. Therefore, it was observed that during different spikes of the pandemic, the spread of infection and its severity changed, encountering more or less hospitalized and severely ill COVID-19 patients. To the best of our knowledge, there are little data on the dynamics of SARS-CoV-2 viral symptoms in elderly patients hospitalized in Romania throughout the last six pandemic waves. Therefore, the purpose of this research was to describe the variance in case severity, symptomatology, ICU hospitalizations, and death among SARS-CoV-2-infected elderly patients in a parallel comparison between six COVID-19 pandemic waves.

**2. Materials and Methods**

**2.1. Study Design and Ethics**

The current research was designed as a retrospective cohort study of hospitalized elderly patients with COVID-19. Patients included in the study were admitted at the Infectious Diseases and Pulmonology Hospital, “Victor Babes”, in the period starting in March 2020 until August 2022. The research protocol was approved on 28 February 2022 by
the Ethics Committee of the “Victor Babes” University of Medicine and Pharmacy from Timisoara, Romania, and by the Ethics Committee of the hospital, with approval number 05. This time span covers both the pre- and post-COVID-19 immunization phases. The study took place at the University of Medicine and Pharmacy “Victor Babes” in Timisoara, under the Infectious Disease Department. The goal of this study was to perform retrospective research by gathering information from the paper and electronic hospital records of elderly patients diagnosed with COVID-19 who were hospitalized during the study period.

2.2. Inclusion Criteria

A database and patient paper record search were conducted to determine the number of elderly patients admitted to the hospital with a SARS-CoV-2 infection. Patients were included if they matched the following criteria: (1) being older than 70 years; (2) their paper records mentioned the ICD-10 diagnosis code of COVID-19; (3) the hospitalization occurred due to SARS-CoV-2 infection as the main diagnosis, without other acute conditions at admission; (4) being vaccinated or unvaccinated against SARS-CoV-2; and (5) having a SARS-CoV-2 infection confirmed by a PCR test. According to existing guidelines, the SARS-CoV-2 infection was considered mild, moderate, or severe as follows: (a) presenting to the hospital with a respiratory distress syndrome or respiratory rates higher than 30/min; (b) the finger oxygen saturation measured after 5 min of rest was lower than 93%; (c) PaO2 (the arterial oxygen partial pressure)/FiO2 (the inspired oxygen fraction) ≤ 300 mmHg; and (d) affected lung area on computed tomography (CT) of more than 50%. The COVID-19 status was defined by a positive polymerase chain reaction test (PCR) from oropharyngeal and nasal swabs using multiplex RT-PCR. A predefined patient personal form was used to gather demographic, clinical, and outcome data from electronic medical records and identify the patients’ age distribution.

The elderly age of being older than 70 years was considered based on several studies that demonstrated a significantly higher proportion of hospital admissions and changes in mortality rates from SARS-CoV-2 infection after passing this age. The acquired patient information was categorized by the pandemic wave at the time of hospital admission as follows: (1) The first wave in Romania was assumed to have occurred between March and October 2020, when Wuhan-Hu-1 (NCBI Reference Sequence: NC 045512.2) was the predominant variation in circulation; (2) the second COVID-19 wave occurred between October 2020 and February 2021, with Clade variants (S: D614G) being the predominant viral strains; (3) the third pandemic wave occurred between February and July 2021, with the Alpha (B.1.1.7) variation being the predominant circulating virus; (4) the fourth COVID-19 wave occurred between July and December of 2021, the Delta (B1617.2) SARS-CoV-2 variant being the most prevalent strain; (5) the Omicron viral strain produced the fifth pandemic wave in Romania between December 2021 and March 2022; (6) lastly, the sixth wave in Romania lasted from March 2022 to July 2022. For each wave, 60 individuals were included in the study, for a total of 360 elderly adults whose gender and comorbidities were matched with a control group of adults younger than 70 years. It was determined using a convenience sampling method that a total minimum of 139 adult patients younger than 70 years that were hospitalized for SARS-CoV-2 infection is sufficient to provide the statistical power needed for the control group.

2.3. Study Variables

The variables considered for analysis were the following: (1) the baseline characteristics of study participants (age, body mass index, gender, area of residence, smoking status, alcohol consumption status, number of comorbidities, COVID-19 vaccination status, and COVID-19 vaccine types); (2) paraclinical findings of the study participants (red blood cell count, white blood cell count, lymphocytes, hemoglobin, hematocrit, alanine aminotransferase, ferritin, erythrocyte sedimentation rate, c-reactive protein, fibrinogen, procalcitonin, d-dimers, interleukin-6, and creatinine; (3) clinical findings and disease outcomes (number of signs and symptoms at admission, clinical signs and symptoms, COVID-19 outcomes,
disease severity, duration of hospitalization, ICU admission, viral clearance, SOFA score, duration of ICU stay, intubated patients, oxygen supplementation, and mortality).

2.4. Statistical Analysis

The statistical analysis was performed with IBM SPSS v.27 (SPSS. Inc., Chicago, IL, USA), while the significance threshold was set for an alpha value of 0.05. The absolute and relative frequencies of categorical variables were computed and compared using the Chi-square and Fisher’s tests. For the comparison of mean rank differences among nonparametric variables, the Kruskal–Wallis test was used. Parametric continuous variables that followed a normal distribution were compared by mean and standard deviation with the ANOVA test (analysis of variance). A Kaplan-Meier curve was plotted for probabilities of mortality based on the sputum culture results, while the Cox regression identified the hazard ratio for mortality in each of the four groups.

3. Results

3.1. Normal Weight vs. Overweight Patients

A total of 360 elderly patients (≥70 years) were included for data analysis, in comparison with a control group of 234 adults younger than 70 years, as presented in Table 1. The two study groups were matched by gender proportions and number of comorbidities. The average age of patients in the control group was 60.9 years, compared to 73.6 years in the group of interest. There were no significant differences in their baseline characteristics, except for the body mass index and vaccination status, which were significantly higher in the older patients, compared with the younger adults (25.6 vs. 24.2, \( p \)-value = 0.002), respectively (15.6% vaccinated patients older than 70 vs. 9.8% in younger adults, \( p \)-value = 0.044). The most commonly used vaccine was the BNT162b2 in 83.9% of older patients, compared to 60.9% in the control group.

Table 1. Comparison of baseline characteristics.

| Baseline Characteristics                  | <70 Years (\( n = 234 \)) | ≥70 Years (\( n = 360 \)) | \( p \)-Value |
|------------------------------------------|-----------------------------|-----------------------------|---------------|
| **Background data**                      |                             |                             |               |
| Age (years), mean ± SD                   | 60.9 ± 7.8                  | 73.6 ± 8.1                  | <0.001        |
| BMI, mean ± SD                           | 24.2 ± 5.0                  | 25.6 ± 5.4                  | 0.002         |
| Gender (men)                             | 129 (55.1%)                 | 198 (55.0%)                 | 0.975         |
| Area of residence (urban)                | 137 (58.5%)                 | 192 (53.3%)                 | 0.211         |
| Smoking                                  | 66 (28.2%)                  | 84 (23.3%)                  | 0.181         |
| Alcohol consumer                         | 29 (12.4%)                  | 46 (12.8%)                  | 0.890         |
| **Number of comorbidities**              |                             |                             | 0.999         |
| 0                                        | 15 (6.4%)                   | 36 (6.4%)                   |               |
| 1                                        | 34 (14.5%)                  | 31 (14.4%)                  |               |
| 2                                        | 106 (45.3%)                 | 72 (45.3%)                  |               |
| ≥3                                       | 79 (33.8%)                  | 74 (33.9%)                  |               |
| **COVID-19 vaccination status**          |                             |                             | 0.044         |
| Yes                                      | 23 (9.8%)                   | 56 (15.6%)                  |               |
| No                                       | 211 (90.2%)                 | 304 (84.4%)                 |               |
| **COVID-19 vaccine**                     |                             |                             | 0.073         |
| BNT162b2 (\( n = 23 \))                 | 14 (60.9%)                  | 47 (83.9%)                  |               |
| mRNA-1273                                | 6 (26.1%)                   | 5 (8.9%)                    |               |
| Ad26.COV2.S                              | 3 (13.0%)                   | 4 (7.1%)                    |               |

Data reported as \( n(\%) \) and calculated using Chi-square test and Fisher’s exact test unless specified differently; BMI—Body Mass Index; BNT162b2—Pfizer BioNTech; mRNA-1273—Moderna; Ad26.COV2.S—Astra Zeneca.

Table 2 presents the paraclinical findings among the two study groups. It was observed that the white blood cell count was significantly higher in the control group compared to the elderly (40.6% of samples outside the normal range vs. 31.9%, \( p \)-value = 0.031). Similarly, the lymphocyte count was decreased in the elderly (44.4% vs. 54.3%, \( p \)-value = 0.019). Among the inflammatory markers, CRP, procalcitonin, and IL-6 were statistically significantly more elevated among patients older than 70 years.
The clinical presentation and outcomes in elderly patients hospitalized with COVID-19 and adult patients are presented in Table 3, and it was observed that older patients had significantly fewer symptoms at admission compared to the younger group. Among clinical signs and symptoms, it was observed that patients older than 70 presented with significantly more digestive symptoms (16.4% vs. 8.5%, *p*-value = 0.005), as well as a higher proportion of them having dyspnea and confusion as presenting symptoms (16.9% vs. 10.3%, *p*-value = 0.022), respectively 10.6% vs. 4.7% (*p*-value = 0.011). Contrarily, fever was significantly more often observed among younger patients (75.6% vs. 66.1%, *p*-value = 0.013).

### Table 2. Paraclinical findings.

| Paraclinical Findings | Normal Range | <70 Years (*n = 234*) | ≥70 Years (*n = 360*) | *p*-Value |
|-----------------------|--------------|------------------------|-----------------------|-----------|
| RBC (millions/mm³)    | 4.35–5.65    | 72 (30.8%)             | 107 (29.7%)           | 0.785     |
| WBC (thousands/mm³)   | 4.5–11.0     | 95 (40.6%)             | 115 (31.9%)           | 0.031     |
| Lymphocytes (thousands/mm³) | 1.0–4.8 | 127 (54.3%)             | 160 (44.4%)           | 0.019     |
| Hemoglobin (g/dL)     | 13.0–17.0    | 55 (23.5%)             | 92 (25.5%)            | 0.571     |
| Hematocrit (%)        | 36–48        | 59 (25.2%)             | 94 (26.1%)            | 0.806     |
| ALT (U/L)             | 7–35         | 67 (28.6%)             | 113 (31.4%)           | 0.475     |
| Ferritin (ng/mL)      | 20–250       | 70 (29.9%)             | 96 (26.7%)            | 0.388     |
| ESR (mm/h)            | 0–22         | 105 (44.9%)            | 189 (51.1%)           | 0.069     |
| CRP (mg/L)            | 0–10         | 83 (35.5%)             | 187 (51.9%)           | 0.001     |
| Fibrinogen (g/L)      | 2–4          | 63 (26.9%)             | 111 (30.8%)           | 0.306     |
| Procalcitonin (ug/L)  | 0–0.25       | 26 (11.1%)             | 69 (19.2%)            | 0.008     |
| D-dimers (ng/mL)      | <250         | 23 (9.8%)              | 54 (15.0%)            | 0.066     |
| IL-6 (pg/mL)          | 0–16         | 53 (22.6%)             | 127 (35.2%)           | 0.001     |
| Creatinine (µmol/L)   | 0.74–1.35    | 14 (6.0%)              | 38 (10.6%)            | 0.054     |

Data reported as % outside the normal range and calculated using the Chi-square test and Fisher’s exact test unless specified differently; RBC—Red Blood Cells; WBC—White Blood Cells; ESR—Erythrocyte Sedimentation Rate; CRP—C-reactive Protein; IL-6—Interleukin 6; ALT—Alanine Aminotransferase.

### Table 3. Clinical presentation and outcomes in elderly patients hospitalized with COVID-19 and adult patients.

| Variables * | <70 Years (*n = 234*) | ≥70 Years (*n = 360*) | *p*-Value |
|-------------|------------------------|-----------------------|-----------|
| Number of signs and symptoms at admission | | | 0.010 |
| 0 | 9 (3.8%) | 36 (10.0%) | |
| 1 | 34 (14.5%) | 50 (13.9%) | |
| 2 | 97 (41.5%) | 163 (45.3%) | |
| ≥3 | 94 (40.2%) | 111 (30.8%) | |
| Clinical signs and symptoms | | | |
| Digestive symptoms | 20 (8.5%) | 59 (16.4%) | 0.005 |
| Anosmia | 42 (17.9%) | 55 (15.3%) | 0.389 |
| Ageusia | 58 (24.8%) | 74 (20.6%) | 0.225 |
| Fatigue | 16 (69.7%) | 267 (74.2%) | 0.229 |
| Dyspnea | 24 (10.3%) | 61 (16.9%) | 0.022 |
| Confusion | 11 (4.7%) | 38 (10.6%) | 0.011 |
| Headache | 23 (9.8%) | 44 (12.2%) | 0.367 |
| Fever | 177 (75.6%) | 238 (66.1%) | 0.013 |
| Cough | 153 (65.4%) | 255 (70.8%) | 0.161 |
| COVID-19 Outcomes | | | |
| Severe COVID-19 | 29 (12.4%) | 71 (19.7%) | 0.019 |
| Severe imaging features | 37 (15.8%) | 83 (23.1%) | 0.031 |
| Mean duration of hospital stay | 12.7 ± 3.3 | 14.1 ± 4.0 | <0.001 |
| Median duration from symptom onset until hospital admission | 4.5 (6.5) | 3.5 (3.0) | <0.001 |
| Viral clearance | 12 (9) | 14 (12) | <0.001 |
| ICU admissions | 18 (7.7%) | 53 (14.7%) | 0.009 |
| Median duration from hospital admission to ICU admission | 5.0 (7.0) | 3.5 (3.0) | <0.001 |
| SOFA score | 4.4 (3.1) | 6.5 (4.8) | <0.001 |
| Median duration of ICU stay | 7.3 (6.6) | 5.6 (4.9) | <0.001 |
| Severe in-hospital complications | 24 (10.3%) | 59 (16.4%) | 0.035 |
| Intubation | 11 (4.7%) | 34 (9.4%) | 0.032 |
| Oxygen supplementation | 86 (36.8%) | 159 (44.2%) | 0.072 |
| Mortality | 8 (3.4%) | 27 (7.5%) | 0.039 |

* Data reported as n (%) and calculated using the Chi-square test and Fisher’s exact test unless specified differently; BMI—Body Mass Index; ICU—Intensive Care Unit; SOFA—Sequential Organ Failure Assessment.
As expected, COVID-19 outcomes were significantly more often affecting the elderly (19.7% vs. 12.4%, \( p \)-value = 0.019). As a consequence, the mean duration of hospitalization was significantly higher than in younger patients (14.1 days vs. 12.7 days, \( p \)-value < 0.001). Additionally, the SOFA score and proportion of patients admitted to the ICU were higher in patients older than 70 years (median SOFA score = 6.5 vs. 4.4, \( p \)-value < 0.001), respectively, with 14.7% ICU admission among the elderly patients, compared to 7.7% in the control group (\( p \)-value = 0.009). The duration of hospitalization and ICU stay were higher in the group of older patients, in correlation with a higher mortality rate of 7.5%, compared to 3.5% among the hospitalized younger patients (\( p \)-value = 0.039).

3.2. Dynamic Comparison of COVID-19 Pandemic Waves

Table 4 describes the clinical findings of elderly patients hospitalized with SARS-CoV-2 infection over six pandemic waves. It was observed that the COVID-19 severity of hospitalized patients was significantly higher during the third and fourth waves (31.7% and 26.7%, compared with the sixth wave of 13.3% severe infections). The mean duration of hospitalization was observed to vary significantly between the six pandemic waves that were analyzed (\( p \)-value < 0.001), with the longest hospital stay being observed during the fourth wave (16.4 days), followed by the first wave with an average of 15.3 days. The shortest hospitalization was during the 5th and 6th waves, with 10.3 and 10.5 days, respectively. Other statistically significant differences between the pandemic waves were the median duration of ICU stay and the proportion of patients requiring oxygen supplementation. The longest median duration of hospitalization was during the first wave (7.1 days), followed by the second wave with 6.6 days, while the shortest ICU stay was during the fourth wave (5.2 days, \( p \)-value = 0.001), as seen in Figure 1a. Despite these differences, the mortality did not significantly change during the six pandemic waves (Figure 1b). Regarding the biological findings measured during the pandemic waves, there was no statistically significant change, as seen in Table 5.

Table 4. Clinical findings of elderly patients (≥70 years old) hospitalized with SARS-CoV-2 infection stratified by COVID-19 pandemic wave.

| Clinical Findings                      | 1st Wave (n = 60) | 2nd Wave (n = 60) | 3rd Wave (n = 60) | 4th Wave (n = 60) | 5th Wave (n = 60) | 6th Wave (n = 60) | \( p \)-Value |
|----------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|--------------|
| Severe COVID-19                         | 11 (18.3%)        | 9 (15.0%)         | 16 (26.7%)        | 19 (31.7%)        | 8 (13.3%)         | 8 (13.3%)         | 0.046        |
| Severe imaging features                 | 12 (20.0%)        | 8 (13.3%)         | 17 (28.3%)        | 21 (35.0%)        | 12 (20.0%)        | 13 (21.7%)        | 0.085        |
| Mean duration of hospital stay          | 15.3 ± 4.0        | 15.0 ± 4.3        | 14.1 ± 4.0        | 16.4 ± 5.2        | 10.3 ± 3.7        | 10.5 ± 3.9        | <0.001       |
| Median duration from symptom onset until hospital admission | 2.0 (2.0)         | 3.0 (2.5)         | 3.5 (3.0)         | 3.0 (2.5)         | 3.5 (3.0)         | 4.0 (2.5)         | 0.122        |
| Viral clearance                         | 15 (11)           | 14 (13)           | 16 (14)           | 15 (12)           | 14 (11)           | 14 (12)           | 0.683        |
| ICU admissions                          | 8 (13.3%)         | 8 (13.3%)         | 12 (20.0%)        | 14 (23.3%)        | 6 (10.0%)         | 5 (8.3%)          | 0.152        |
| Median duration from hospital admission to ICU admission | 5.0 (3.0)         | 4.5 (3.5)         | 4.0 (3.0)         | 3.5 (3.0)         | 3.5 (3.0)         | 4.0 (3.5)         | 0.360        |
| SOFA score                              | 5.6 (4.6)         | 5.8 (4.8)         | 6.7 (4.9)         | 6.5 (4.3)         | 6.8 (5.0)         | 6.5 (4.8)         | 0.062        |
| Median duration of ICU stay             | 7.1 (3.4)         | 6.6 (3.9)         | 5.7 (4.0)         | 5.2 (3.5)         | 5.4 (3.4)         | 5.9 (4.2)         | 0.001        |
| Severe in-hospital complications        | 7 (11.7%)         | 8 (13.3%)         | 13 (21.9%)        | 15 (25.0%)        | 7 (11.7%)         | 9 (15.0%)         | 0.227        |
| Intubation                              | 4 (6.7%)          | 5 (8.3%)          | 7 (11.7%)         | 10 (16.7%)        | 4 (6.7%)          | 4 (6.7%)          | 0.334        |
| Oxygen supplementation                  | 21 (35.0%)        | 24 (40.0%)        | 35 (58.3%)        | 36 (60.0%)        | 20 (33.3%)        | 23 (38.3%)        | 0.004        |
| Mortality                               | 3 (5.0%)          | 3 (5.0%)          | 5 (8.3%)          | 9 (15.0%)         | 4 (6.7%)          | 3 (5.0%)          | 0.215        |

Data reported as \( n \) (%) and calculated using the Chi-square test and Fisher’s exact test unless specified differently; ICU—Intensive Care Unit; SOFA—Sequential Organ Failure Assessment.

Table 5. Paraclinical findings of elderly patients (≥70 years old) hospitalized with SARS-CoV-2 infection stratified by COVID-19 pandemic wave.

| Paraclinical Findings          | Normal Range | 1st Wave (n = 60) | 2nd Wave (n = 60) | 3rd Wave (n = 60) | 4th Wave (n = 60) | 5th Wave (n = 60) | 6th Wave (n = 60) | \( p \)-Value |
|-------------------------------|--------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|--------------|
| RBC (millions/mm\(^3\))       | 4.35–5.65    | 20 (32.8%)        | 23 (37.7%)        | 13 (21.3%)        | 17 (27.9%)        | 16 (26.2%)        | 18 (29.5%)        | 0.454        |
| WBC (thousands/mm\(^3\))     | 4.5–11.0     | 18 (29.5%)        | 23 (37.7%)        | 16 (26.2%)        | 21 (34.4%)        | 20 (32.8%)        | 17 (27.9%)        | 0.750        |
Table 5. Cont.

| Paraclinical Findings         | Normal Range | 1st Wave (n = 60) | 2nd Wave (n = 60) | 3rd Wave (n = 60) | 4th Wave (n = 60) | 5th Wave (n = 60) | 6th Wave (n = 60) | p-Value |
|------------------------------|--------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|---------|
| Lymphocytes (thousands/mm³)  | 1.0–4.8      | 24 (40.0%)        | 23 (38.3%)        | 28 (46.7%)        | 29 (48.3%)        | 26 (43.3%)        | 30 (50.0%)        | 0.752   |
| Hemoglobin (g/dL)            | 13.0–17.0    | 13 (21.3%)        | 18 (29.5%)        | 14 (23.0%)        | 14 (23.0%)        | 17 (27.9%)        | 16 (26.2%)        | 0.889   |
| Hematocrit (%)               | 36–48        | 14 (23.0%)        | 18 (29.5%)        | 15 (25.0%)        | 16 (26.7%)        | 14 (23.0%)        | 17 (27.9%)        | 0.949   |
| ALT (U/L)                    | 7–35         | 17 (27.9%)        | 19 (31.7%)        | 20 (33.3%)        | 27 (45.0%)        | 17 (27.9%)        | 13 (21.3%)        | 0.134   |
| Ferritin (ng/mL)             | 20–250       | 15 (25.0%)        | 12 (20.0%)        | 16 (26.7%)        | 17 (27.9%)        | 12 (20.0%)        | 14 (23.3%)        | 0.855   |
| ESR (mm/h)                   | 0–22         | 32 (53.3%)        | 30 (50.0%)        | 28 (46.7%)        | 36 (60.0%)        | 35 (58.3%)        | 28 (46.7%)        | 0.552   |
| CRP (mg/L)                   | 0–10         | 29 (48.3%)        | 31 (51.7%)        | 27 (45.0%)        | 38 (63.3%)        | 32 (53.3%)        | 30 (50.0%)        | 0.449   |
| Fibrinogen (g/L)             | 2–4          | 19 (31.7%)        | 18 (29.5%)        | 15 (25.0%)        | 17 (27.9%)        | 20 (33.3%)        | 21 (34.5%)        | 0.871   |
| Procalcitonin (ug/L)         | 0–0.25       | 11 (18.3%)        | 9 (15.0%)         | 13 (21.7%)        | 15 (25.0%)        | 15 (25.0%)        | 9 (15.0%)         | 0.555   |
| D-dimers (ng/mL)             | <250         | 10 (16.7%)        | 11 (15.0%)        | 9 (15.0%)         | 13 (21.7%)        | 14 (23.0%)        | 10 (16.7%)        | 0.839   |
| IL-6 (pg/mL)                 | 0–16         | 21 (34.4%)        | 20 (32.8%)        | 23 (37.7%)        | 22 (36.7%)        | 24 (40.0%)        | 17 (27.9%)        | 0.813   |
| Creatinine (µmol/L)          | 0.74–1.35    | 8 (13.3%)         | 8 (13.3%)         | 6 (10.0%)         | 9 (15.0%)         | 4 (6.7%)          | 5 (8.3%)          | 0.659   |

Data reported as % outside the normal range and calculated using the Chi-square test and Fisher’s exact test unless specified differently; RBC—Red Blood Cells; WBC—White Blood Cells; ESR—Erythrocyte Sedimentation Rate; CRP—C-reactive Protein; IL-6—Interleukin 6; ALT—Alanine Aminotransferase.

Figure 1. (a,b) Dynamic comparison of ICU admissions and mortality in elderly patients (≥70 years old) hospitalized with SARS-CoV-2 infection during six COVID-19 pandemic waves.

3.3. Risk Analysis

The risk analysis for ICU admission in SARS-CoV-2 infected elderly patients was evaluated in Table 6, in comparison with the control group of adults younger than 70. It was observed that the SARS-CoV-2 infection during the first, third, and fourth pandemic waves had a significantly higher risk for mortality, as seen in Figure 2. Among the clinical and paraclinical predictors for ICU admission in the elderly, it was observed that confusion and dyspnea at admission were significant risk factors ($\beta = 1.92$ and $\beta = 3.65$, respectively). The laboratory parameters identified decreased lymphocytes ($\beta = 2.11$), elevated IL-6 ($\beta = 1.96$), and procalcitonin ($\beta = 2.46$) as the most significant risk factors for ICU admission in the admitted elderly patients.

Table 6. Regression analysis for risk of ICU admission in SARS-CoV-2-infected elderly patients.

| Covariates (predictors)—pandemic waves | \( \beta \) for ICU Admission * | (95% CI of \( \beta \)) | Significance |
|-----------------------------------------|-------------------------------|------------------------|-------------|
| ≥70 years (constant) *                  | 1.93                          | 1.15–3.66              | 0.020       |
| 1st pandemic wave                       | 2.12                          | 1.48–4.20              | 0.004       |
| 2nd pandemic wave                       | 1.59                          | 0.92–2.84              | 0.261       |
| 3rd pandemic wave                       | 2.36                          | 1.28–3.78              | 0.033       |
| 4th pandemic wave                       | 2.04                          | 1.13–4.09              | 0.028       |
| 5th pandemic wave                       | 1.33                          | 0.90–1.83              | 0.402       |
| 6th pandemic wave                       | 1.58                          | 0.87–1.96              | 0.317       |
Table 6. Cont.

| Covariates (predictors)—clinical and paraclinical | \( \beta \) for ICU Admission * | (95% CI of \( \beta \)) | Significance |
|--------------------------------------------------|---------------------------------|------------------------|--------------|
| Confusion                                        | 1.92                            | 1.20–2.47              | 0.001        |
| Dyspnea                                          | 3.65                            | 1.46–5.39              | <0.001       |
| Decreased WBC                                    | 1.09                            | 0.91–1.43              | 0.063        |
| Decreased lymphocytes                            | 2.11                            | 1.34–3.06              | <0.001       |
| Elevated procalcitonin                           | 2.46                            | 1.52–3.88              | <0.001       |
| Elevated IL-6                                    | 1.96                            | 1.31–2.95              | 0.001        |
| Elevated CRP                                     | 1.13                            | 0.98–1.42              | 0.051        |

* Dependent (response) variable; ^ Estimated risk in univariate analysis; CI—Confidence Interval.

Figure 2. Kaplan-Meier probability analysis for mortality in elderly patients based on the pandemic wave.

4. Discussion

4.1. Literature Findings

In all six waves, fever, cough, and tiredness were the symptoms that occurred most often. Concomitant symptoms that occurred less frequently included a runny nose, headache, and digestive symptoms. Although the first, third, and fourth pandemic waves were observed to bring a significantly higher risk for mortality in the elderly patients hospitalized for COVID-19, the bias risk has to be weighed, considering that the patients admitted to a tertiary clinic and treated were the most difficult cases. Therefore, during peak pandemic waves, it was possible that only the more severe cases were hospitalized. These findings are consistent with previous research [1]; although, we did not evaluate the Pneumonia Severity Index (PSI) score, which was reported to be greater when compared to young and middle-aged adults. It is important to note that among senior patients, the proportion of patients complaining of more severe dyspnea and tachypnea was greater in patients admitted to the ICU, as well as delirium and abdominal discomfort that may accompany cases with a severe evolution [45]. On the other side, constitutional symptoms such as fever and headache were more prevalent in survivors.

Increasing numbers of investigations have shown that older people may have unusual clinical presentations, with fever appearing less commonly in older patients than in younger patients, which was consistent with our findings [46]. Moreover, it appears that delirium and neuropsychiatric symptoms in this patient population are increasing significantly
in COVID-19 patients older than 70 years. In a recent meta-analysis of patients with SARS-CoV-2 infection, the prevalence of delirium was almost 30% in those older than 65, compared to less than 15% in the general hospitalized adult population [47], which was associated with an approximately 45% mortality when delirium was present at admission.

Regarding the laboratory findings, it was shown that older patients did not vary significantly from other adults in terms of their WBC, NLR, and procalcitonin levels, although lymphocytes found in the elderly were much lower than in the adult population. On the other hand, the level of CRP found in older individuals was shown to be significantly greater [48]. A comparison of the laboratory findings between the group of elderly patients who survived SARS-CoV-2 infection and those who did not, based on a follow-up period of four weeks, revealed that the number of neutrophils had significantly increased, whereas the number of lymphocytes, monocytes, and platelets had decreased among the deceased patients during the later phases of the infection. However, they did not follow the evolution of laboratory parameters during hospitalization, only at admission. Other findings were that the prothrombin time was considerably extended, coupled with an increase in kidney markers, cardiac markers, and D-dimers [49].

Other studies reported similar results when analyzing hospitalized patients who survived the SARS-CoV-2 infection, identifying that the older population exhibited lower levels of ferritin, procalcitonin, and lymphocytes. It has also been shown that elevated levels of D-dimers, CRP, and a high NLR score are related to a worse prognosis [50], where elevated D-dimers had the best sensitivity and specificity for negative outcomes, followed by CRP levels and NLR score. Other studies that researched the conventionally tested biological markers found an association between LDH and AST with lower pulmonary function, ICU admission, and death [51]. In other investigations, including older individuals with COVID-19, other variables related to mortality, such as frailty, have also been reported. For instance, a recent systematic study that included data from almost one million individuals indicates that frailty and being underweight increased the chance of SARS-CoV-2 infection-associated death by more than five-fold [52].

Prompt identification of COVID-19-related complications is of extreme importance in vulnerable patients such as the elderly. In this case, chest imaging is the most important diagnostic technique for determining pulmonary complications during acute SARS-CoV-2 infection. A bilateral multilobar ground-glass opacification with a peripheral or posterior distribution, primarily in the lower lobes, is one of the typical hallmarks of COVID-19 [53]. In a limited number of instances, particularly those affecting old patients, an atypical first imaging appearance of consolidative opacities superimposed over ground-glass opacity may be seen. It was observed that the elderly had a significantly higher incidence of multiple lobe involvement compared to the younger and middle-aged groups [54].

Although there were more older patients who were vaccinated than younger adults in our cohort, the severity of SARS-CoV-2 infection was much greater among the elderly. It is well advised that the elderly are a high-risk population that should be provided immunization with priority, but it was observed that the antibody response after vaccination was typically lower due to the steady reduction of the immune system with age and the immunological response of neutralizing antibodies after vaccination dropped more abruptly in older individuals than the adult patients with the same vaccines and number of doses [55]. On the contrary, it was also observed that in patients older than 60 years, the rates of severe SARS-CoV-2 infections were significantly lower by almost 20% among those who received a third booster dose of the Pfizer-BioNTech vaccine compared to those who did not receive the third dose [56]. However, current findings show that mRNA-based COVID-19 vaccination boosters are effective against the Omicron variant, but with a lower effect; although, data on the elderly are few [57].

This research identified substantial differences between the six COVID-19 pandemic waves in Romania. Similar studies are few on reporting a complete comparison of each wave with the purpose of determining the variability of SARS-CoV-2 mutations and severity of infections. Another study that took place in Thailand showed that the severity of the
third wave represented by the Delta strain was greater than that of prior waves, which is similar to our findings [58]. It is, however, unknown if the difference is attributable to the absence of effective social distancing measures and public health initiatives or a more dangerous mutation of the SARS-CoV-2 virus. On the other hand, the greatest detrimental effects on public health were caused by the first wave. Another study comparing Delta solely and Omicron found a case fatality ratio of 3.4% for Delta and 1.9% for Omicron, indicating a difference of around twice. Consequently, Omicron is less severe than Delta based on these metrics, with the exact severity reduction compared to Delta depending on how the number of infections is assessed [59].

4.2. Study Limitations and Strengths

As a first limitation, there is the possibility of human error in the creation of digital data from paper medical records, and the quality of the data that was studied in a retrospective cohort design may have been lower than expected. The second constraint is that there was a very low number of participants in each individual group’s sample, despite the fact that the total number of participants was sufficient to satisfy the statistical power requirements. The third limitation of the current study would be the monocentric design, which can limit the generalization of our findings. A higher rate of COVID-19 complications at admission can occur in patients with multiple comorbidities. To prevent the bias risk of multiple comorbidities in elderly patients, it was opted to include in the study only patients admitted for SARS-CoV-2 infection, excluding those who got infected during their hospital stay for a different diagnosis. Comorbidities such as arterial hypertension and diabetes mellitus were identified more often in some of the study groups, predisposing them to worse outcomes and higher mortality rates, as they seem to be related to a more severe infection [60,61]. Lastly, patients with a previous infection are presumed to develop a stronger immunity against the virus, which could distort the result in this study [62,63]. However, the only way to verify if a patient had a previous SARS-CoV-2 infection or hospitalization for COVID-19 was to check in the hospital’s database if the patient was admitted before, and it was not possible to check if the patient was admitted elsewhere.

5. Conclusions

Although elderly patients are likely to have worse COVID-19 outcomes during hospitalization, the risk is weighted by the higher proportion of comorbidities and frailty of the elderly. The six pandemic waves that were particularly analyzed did not show significantly disproportionate differences regarding patient mortality; although, during the fourth wave, there were probably more patients with severe COVID-19 admitted to the hospital. It is likely that some circulating SARS-CoV-2 viral strains were more contagious, causing more infections and creating an overload on the healthcare systems, which might explain the changes observed in our study. Biological parameters also did not vary significantly among the elderly patients during the six waves that were analyzed, although patients older than 70 were more likely to present with dyspnea, confusion, and digestive symptoms, associated with lower lymphocyte levels and higher IL-6 levels. It is, therefore, difficult to diagnose and treat elderly people who have SARS-CoV-2 infection because they are more prone to developing severe clinical consequences from the virus. According to the information that is now available, a customized strategy that targets both the positive and negative consequences of therapy choices need to be made available to older persons. It is imperative that hospitals and residential care facilities that provide long-term care immediately develop appropriate healthcare plans for their older patients. To ensure that COVID-19 patients have access to the most productive therapy choices, fragility must be addressed. Until further advancements can be made in therapy, it is advised that the elderly population be kept isolated from the rest of the community when COVID-19 epidemics occur.
Author Contributions: Conceptualization: R.M.F. and O.R.; methodology: R.M.F. and O.R.; software: V.B. (Vlad Bloanca) and V.B. (Vlad Barbos); validation: C.C.; formal analysis: C.C.; investigation: D.M.; resources: D.M.; data curation: V.B. (Vlad Bloanca) and V.B. (Vlad Barbos); writing—original draft preparation: R.M.F. and V.B. (Vlad Bloanca); writing—review and editing: A.-O.T., M.R. and E.B.; visualization: A.-O.T. and E.B.; supervision: C.D. and C.O.; project administration: C.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Victor Babes’ Clinical Hospital for Infectious Diseases and Pulmonology in Timisoara on 28 February 2022 with approval number 05.

Informed Consent Statement: Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement: Data available on request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Perrotta, F.; Corbi, G.; Mazzeo, G.; Bocci, M.; Aronne, L.; D’Agnano, V.; Komici, K.; Mazzarella, G.; Parrella, R.; Bianco, A. COVID-19 and the elderly: Insights into pathogenesis and clinical decision-making. Aging Clin. Exp. Res. 2020, 32, 1599–1608. [CrossRef]

2. Lebrasseur, A.; Fortin-Bédard, N.; Lettre, J.; Raymond, E.; Bussières, E.-L.; Lapierre, N.; Faieta, J.; Vincent, C.; Duchesne, L.; Ouellet, M.-C.; et al. Impact of the COVID-19 Pandemic on Older Adults: Rapid Review. JMIIR Aging 2021, 4, e26474. [CrossRef]

3. Grigoras, M.L.; Citu, I.M.; Citu, C.; Chiriac, V.D.; Gorun, F.; Levai, M.C.; Manolescu, D.; Rosca, O.; Bratosin, F.; Gurumurthy, S.; et al. Evaluation of FIB-4, NFS, APRI and Liver Function Tests as Predictors for SARS-CoV-2 Infection in the Elderly Population: A Matched Case-Control Analysis. J. Clin. Med. 2022, 11, 5149. [CrossRef]

4. Myall, K.J.; Martinovic, J.L.; West, A. How COVID-19 interacts with interstitial lung disease. Breathe 2022, 18, 210158. [CrossRef]

5. Farshbafnadi, M.; Zonouzi, S.K.; Sabahi, M.; Dolatshahi, M.; Arab, M.H. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp. Gerontol. 2021, 154, 115107. [CrossRef] [PubMed]

6. Chiumello, D.; Modafferi, L.; Fratti, I. Risk Factors and Mortality in Elderly ARDS COVID-19 Compared to Patients without COVID-19. J. Clin. Med. 2022, 11, 5180. [CrossRef] [PubMed]

7. Citu, C.; Burlea, B.; Gorun, F.; Motoc, A.; Gorun, O.M.; Malita, D.; Ratiu, A.; Margan, R.; Grigoras, M.L.; Bratosin, F.; et al. Predictive Value of Blood Coagulation Parameters in Poor Outcomes in COVID-19 Patients: A Retrospective Observational Study in Romania. J. Clin. Med. 2022, 11, 2831. [CrossRef] [PubMed]

8. Mendiola-Pastrana, I.R.; López-Ortiz, E.; de la Loza-Zamora, J.G.R.; González, J.; Gómez-García, A.; López-Ortiz, G. SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. Life 2022, 12, 170. [CrossRef]

9. Maurya, R.; Mishra, P.; Swaminathan, A.; Ravi, V.; Saifi, S.; Kanakan, A.; Mehta, P.; Devi, P.; Praveen, S.; Budhiraja, S.; et al. SARS-CoV-2 Mutations and COVID-19 Clinical Outcome: Mutation Global Frequency Dynamics and Structural Modulation Hold the Key. Front. Cell. Infect. Microbiol. 2022, 12, 686414. [CrossRef]

10. ISARIC Clinical Characterisation Group. COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. Infection 2021, 49, 889–905. [CrossRef]

11. Pouw, N.; van de Maat, J.; Veerman, K.; Oever, J.T.; Janssen, N.; Abbink, E.; Reijers, M.; de Mast, Q.; Hoefsloot, W.; van Crevel, R.; et al. COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study. PLoS ONE 2021, 16, e0248713. [CrossRef] [PubMed]

12. Pilut, C.N.; Citu, C.; Gorun, F.; Bratosin, F.; Gorun, O.M.; Burlea, B.; Citu, I.M.; Grigoras, M.L.; Manolescu, D.; Gluhovschi, A. The Utility of Laboratory Parameters for Cardiac Inflammation in Heart Failure Patients Hospitalized with SARS-CoV-2 Infection. Diagnostics 2022, 12, 824. [CrossRef] [PubMed]

13. Fabião, J.; Sassi, B.; Pedrollo, E.; Gerchman, F.; Kramer, C.; Leitão, C.; Pinto, L. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz. J. Med Biol. Res. 2022, 55, e11711. [CrossRef] [PubMed]

14. Fortunato, F.; Martinelli, D.; Caputo, S.L.; Santantonio, T.; Dattoli, V.; Lopalco, P.L.; Prato, R. Sex and gender differences in COVID-19: An Italian local register-based study. BMJ Open 2021, 11, e051506. [CrossRef] [PubMed]

15. Jin, J.M.; Bai, P.; He, W.; Wu, F.; Liu, X.F.; Han, D.M.; Liu, S.; Yang, J.K. Gender Differences in Patients with COVID-19: Focus on Severity and Mortality. Front. Public Health 2020, 8, 152. [CrossRef]

16. de Souza, G.A.P.; Le Bideau, M.; Boschi, C.; Ferreira, L.; Wurtz, N.; Devaux, C.; Colson, P.; La Scola, B. Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells. Viruses 2021, 14, 23. [CrossRef]
17. Fericean, R.M.; Citu, C.; Manolescu, D.; Rosca, O.; Bratosin, F.; Tudorache, E.; Oancea, C. Characterization and Outcomes of SARS-CoV-2 Infection in Overweight and Obese Patients: A Dynamic Comparison of COVID-19 Pandemic Waves. *J. Clin. Med.* **2022**, *11*, 2916. [CrossRef]

18. Jung, C.; Fjelner, J.; Bruno, R.R.; Wernly, B.; Artigas, A.; Pinto, B.B.; Scheinfeld, J.C.; Wolff, G.; Kelm, M.; Beil, M.; et al. Differences in mortality in critically ill elderly patients during the second COVID-19 surge in Europe. *Crit. Care* **2021**, *25*, 344. [CrossRef]

19. Gkoufa, A.; Maneta, E.; Ntoumas, G.N.; E Georgakopoulou, V.; Mantelou, A.; Kokkoris, S.; Routsi, C. Elderly adults with COVID-19 admitted to intensive care unit: A narrative review. *World J. Crit. Care Med.* **2021**, *10*, 278–289. [CrossRef]

20. Papava, I.; Dehelean, L.; Rosman, R.S.; Bondrescu, M.; Dimeny, C.Z.; Domuta, E.M.; Bratosin, F.; Bogdan, I.; Grigoras, M.L.; Tigmeanu, C.V.; et al. The Impact of Hyper-Acute Inflammatory Response on Stress Adaptation and Psychological Symptoms of COVID-19 Patients. *Int. J. Environ. Res. Public Health* **2022**, *19*, 6501. [CrossRef]

21. Rangappa, P. Cytokine Storm and Immunomodulation in COVID-19. *Indian J. Crit. Care Med.* **2021**, *25*, 1288–1291. [CrossRef] [PubMed]

22. Pinheiro, M.M.; Fabbri, A.; Infante, M. Cytokine storm modulation in COVID-19: A proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4). *Immunotherapy* **2021**, *13*, 753–765. [CrossRef] [PubMed]

23. Manolescu, D.; Timar, B.; Bratosin, F.; Rosca, O.; Citu, C.; Oancea, C. Predictors for COVID-19 Complete Remission with HRCT Pattern Evolution: A Monocentric, Prospective Study. *Diagnostics* **2022**, *12*, 1397. [CrossRef] [PubMed]

24. Starke, K.R.; Reissig, D.; Peterit-Haack, G.; Schmauder, S.; Nienhaus, A.; Seidler, A. The isolated effect of age on the risk of COVID-19 severe outcomes: A systematic review with meta-analysis. *BMJ Glob. Health* **2021**, *6*, e006434. [CrossRef]

25. Bogdan, I.; Citu, C.; Bratosin, F.; Malita, D.; Rosman, I.; Gurban, C.V.; Bota, A.V.; Turaiche, M.; Bratu, M.L.; Pilut, C.N.; et al. The Impact of Multiplex PCR in Diagnosing and Managing Bacterial Infections in COVID-19 Patients Self-Medicated with Antibiotics. *Antibiotics* **2022**, *11*, 437. [CrossRef]

26. Rouatbi, S. The aging lung face to COVID-19. *Tunis Med.* **2022**, *100*, 91–94.

27. Marincu, I.; Citu, C.; Bratosin, F.; Bogdan, I.; Timircan, M.; Gurban, C.V.; Bota, A.V.; Braescu, L.; Grigoras, M.L. Clinical Characteristics and Outcomes of COVID-19 Hospitalized Patients: A Comparison between Complete mRNA Vaccination Profile and Natural Immunity. *J. Pers. Med.* **2022**, *12*, 259. [CrossRef]

28. Chemaitelly, H.; Abu-Raddad, L.J. Waning effectiveness of COVID-19 vaccines. *Lancet* **2022**, *399*, 771–773. [CrossRef]

29. Citu, I.M.; Citu, C.; Gorun, F.; Sas, I.; Bratosin, F.; Motoc, A.; Burlea, B.; Rosca, O.; Malita, D.; Gorun, O.M. The Risk of Spontaneous Abortion Does Not Increase Following First Trimester mRNA COVID-19 Vaccination. *J. Clin. Med.* **2022**, *11*, 1698. [CrossRef]

30. Moghadas, S.M.; Vilches, T.N.; Zhang, K.; Wells, C.R.; Meyers, L.A.; Neuzil, K.M.; Langley, J.M.; Fitzpatrick, M.C.; et al. The impact of vaccination on COVID-19 outbreaks in the United States. *Clin. Infect. Dis.* **2021**, *73*, 2257–2264. [CrossRef]

31. Citu, I.M.; Citu, C.; Gorun, F.; Sas, I.; Tomescu, L.; Neamtu, R.; Motoc, A.; Gorun, O.M.; Burlea, B.; Bratosin, F.; et al. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester. *Viruses* **2022**, *14*, 307. [CrossRef] [PubMed]

32. World Health Organization. ICD-10: *International Statistical Classification of Diseases and Related Health Problems: Tenth Revision*, 2nd ed.; World Health Organization: Geneva, Switzerland, 2004; Available online: https://apps.who.int/iris/handle/10665/42980 (accessed on 14 November 2022).

33. Hu, J.; Wang, Y. The Clinical Characteristics and Risk Factors of Severe COVID-19. *Gerontology* **2021**, *67*, 255–266. [CrossRef] [PubMed]

34. Cerbu, B.; Pantea, S.; Bratosin, F.; Vidican, I.; Turaiche, M.; Frent, S.; Borsi, E.; Marincu, I. Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic. *Medicina* **2021**, *57*, 597. [CrossRef]

35. Tombuloglu, H.; Sabit, H.; Al-Khallaf, H.; Kabanja, J.H.; Alsaeeed, M.; Al-Saleh, N.; Al-Suhaimi, E. Multiplex real-time RT-PCR method for the diagnosis of SARS-CoV-2 by targeting viral N, RdRP and human RP genes. *Sci. Rep.* **2022**, *12*, 2853. [CrossRef]

36. Gómez-Belda, A.B.; Fernández-Garcés, M.; Mateo-Sánchez, E.; Madrazo, M.; Carmona, M.; Piles-Roger, L.; Artero, A. COVID-19 in older adults: What are the differences with younger patients? *Geriatr Gerontol Int.* **2021**, *21*, 60–65. [CrossRef]

37. Prendki, V.; Tiseo, G.; Falcone, M. Caring for older adults during the COVID-19 pandemic. *Clin. Microbiol. Infect.* **2021**, *27*, 785–791. [CrossRef] [PubMed]

38. Steenblock, C.; Schwarz, P.E.H.; Ludwig, B.; Linkermann, A.; Zimmet, P.; Kulebyakina, K.; Tkachuk, V.A.; Markov, A.G.; Lehner, H.; de Angelis, M.H.; et al. COVID-19 and metabolic disease: Mechanisms and clinical management. *Lancet Diabetes Endocrinol.* **2021**, *9*, 786–798. [CrossRef]

39. Ganji, R.; Reddy, P.H. Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases. *Front. Aging Neurosci.* **2021**, *12*, 614650. [CrossRef]

40. Lazar, M. Sequencing of the SARS-CoV-2 Virus Genome in Romania. National Institute of Medical-Military Research and Development “Cantacuzino”. Available online: https://cantacuzino.mapn.ro/pages/view/249 (accessed on 5 August 2022).

41. Hodcroft, E.B.; Zuber, M.; Nadeau, S.; Vaughan, T.G.; Crawford, K.H.D.; Althaus, C.L.; Reichmuth, M.L.; Bowen, J.E.; Walls, A.C.; Corti, D.; et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *Nature* **2021**, *595*, 707–712. [CrossRef]

42. Dascalu, S.; Geambasu, O.; Rau, C.V.; Azoicai, D.; Popovici, E.D.; Apetrei, C. COVID-19 in Romania: What Went Wrong? *Front. Public Health* **2021**, *9*, 813941. [CrossRef]

16. Marincu, I.; Citu, C.; Manolescu, D.; Rosca, O.; Bratosin, F.; Tudorache, E.; Oancea, C. Characterization and Outcomes of SARS-CoV-2 Infection in Overweight and Obese Patients: A Dynamic Comparison of COVID-19 Pandemic Waves. *J. Clin. Med.* **2022**, *11*, 2916. [CrossRef]
43. Streinu-Cercel, A.; Sândulescu, O.; Miron, V.D.; Parasciv, S.; Casangiu, C.; Hohan, R.; Bănică, L.; Surlac, M.; Streinu-Cercel, A. Undetected Omicron Transmission in Romania—Report of the First Detected Case of Locally Acquired Omicron Infection and Complete Epidemiological Investigation. *Diagonstics* 2022, 12, 348. [CrossRef] [PubMed]

44. Popa, A.D.; Antoniu, S.A.; Enache, A.I.; Popa, I.V.; Dragomir, R.A.; Burlacu, A. Development and Validation of a Questionnaire to Assess Knowledge and Attitudes towards COVID-19 Preventive Measures in Romania. *Healthcare* 2022, 10, 1827. [CrossRef]

45. Goetzl, E.J.; Huang, M.; Kon, J.; Patel, K.; Schwartz, J.B.; Fast, K.; Ferrucci, L.; Madara, K.; Taub, D.D.; Longo, D.L. Gender specificity of altered human immune cytokine profiles in aging. *FASEB J.* 2010, 24, 3580–3589. [CrossRef] [PubMed]

46. Vigezzi, G.P.; Bertuccio, P.; Amerio, A.; Bosetti, C.; Gori, D.; Cavalieri d’Oro, L.; Iacoviello, L.; Stuckler, D.; Zucchi, A.; Gallus, S.; et al. Lost Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. *Adv. Prev. Med.* 2021, 1180–1188. [CrossRef] [PubMed]

47. Shao, S.C.; Lai, C.C.; Chen, Y.H.; Chen, Y.C.; Hung, M.J.; Liao, C.-C. Prevalence, incidence and mortality of delirium in patients with COVID-19: A sys-tematic review and meta-analysis. *Age Ageing* 2021, 50, 1445–1453. [CrossRef]

48. Liu, K.; Chen, Y.; Lin, R.; Han, K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *J. Infect.* 2020, 80, e14–e18. [CrossRef] [PubMed]

49. Wang, L.; He, W.; Yu, X.; Hu, D.; Bao, M.; Liu, H.; Zhou, J.; Jiang, H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J. Infect.* 2020, 80, 639–645. [CrossRef]

50. Bastug, A.; Bodur, H.; Erdogan, S.; Gokcinar, D.; Kazancioglu, S.; Kosovali, B.D.; Ozbay, B.O.; Gok, G.; Turan, I.O.; Yilmaz, G.; et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. *Int. Immunopharmacol.* 2020, 88, 106950. [CrossRef] [PubMed]

51. Battaglini, D.; Lopes-Pacheco, M.; Castro-Faria-Neto, H.C.; Pelosi, P.; Rocco, P.R.M. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. *Front. Immunol.* 2022, 13, 857573. [CrossRef]

52. Saragih, I.D.; Advani, S.; Saragih, I.S.; Suarilah, I.; Susanto, I.; Lin, C.-J. Frailty as a Mortality Predictor in Older Adults with COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies. *Geriatr. Nurs.* 2021, 42, 983–992. [CrossRef]

53. Rinaldi, L.; Milione, S.; Fascione, M.C.; Pafundi, P.C.; Altruda, C.; Di Caterino, M.; Monaco, L.; Reginelli, A.; Perrotta, F.; Porta, G.; et al. Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: A multicentre prospective study. *Respirology* 2019, 25, 535–542. [CrossRef] [PubMed]

54. Singhal, S.; Kumar, P.; Singh, S.; Saha, S.; Dey, A.B. Clinical features and outcomes of COVID-19 in older adults: A systematic review and meta-analysis. *BMC Geriatr.* 2021, 21, 321. [CrossRef]

55. Newman, J.; Thakur, N.; Peacock, T.P.; Bialy, D.; Elrefaey, A.M.E.; Bogaardt, C.; Horton, D.L.; Ho, S.; Kankeyan, T.; Carr, C.; et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. *Nat. Microbiol.* 2022, 7, 1180–1188. [CrossRef] [PubMed]

56. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Faculty Opinions recommendation of Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *FASEB J.* 2022, 36, 8080–8090. [CrossRef] [PubMed]

57. Garcia-Beltran, W.F.; St Denis, K.J.; Hoelzemer, A.; Lam, E.C.; Nittido, A.D.; Sheehan, M.L.; Berrios, C.; Ofoman, O.; Chang, C.C.; Hauser, B.M.; et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron vari-ant. *Cell* 2022, 185, 457–466. [CrossRef]

58. Kunno, J.; Supawattanabodee, B.; Sunamasrithakul, C.; Wiriyasivaj, B.; Kuratong, S.; Kaewchandee, C. Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. *Adv. Prev. Med.* 2021, 2021, 5807056. [CrossRef]

59. Sigal, A.; Milo, R.; Jassat, W. Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. *Nat. Rev. Immunol.* 2022, 22, 267–269. [CrossRef]

60. Behera, J.; Ison, J.; Voor, M.J.; Tyagi, S.C.; Tyagi, N. Diabetic Covid-19 severity: Impaired glucose tolerance and pathologic bone loss. *Biochem. Biophys. Res. Commun.* 2022, 620, 180–187. [CrossRef]

61. Peng, M.; He, J.; Xue, Y.; Yang, X.; Liu, S.; Gong, Z. Role of Hypertension on the Severity of COVID-19: A Review. *J. Cardiovasc. Pharmacol.* 2021, 78, e648–e655. [CrossRef]

62. Dhillon, R.A.; Qamar, M.A.; Gilani, J.A.; Irfan, O.; Waqar, U.; Sajid, M.I.; Mahmood, S.F. The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. *Ann. Med. Surg.* 2021, 72, 103130. [CrossRef]

63. Ren, X.; Zhou, J.; Guo, J.; Hao, C.; Zheng, M.; Zhang, R.; Huang, Q.; Yao, X.; Li, R.; Jin, Y. Reinfection in patients with COVID-19: A systematic review. *Glob. Health Res. Policy* 2022, 7, 12. [CrossRef] [PubMed]